Upstream Bio to Participate in the Piper Sandler 36th Annual Healthcare Conference
November 21, 2024 08:00 ET
|
Upstream Bio
Upstream Bio CEO to participate in fireside chat at Piper Sandler
COPD and Asthma Devices Market Projected to Reach $44.95 Billion in 2024 with Continued Expansion through 2028, Driven by Technological Innovations and Rising Prevalence - Forecasts to 2033
November 07, 2024 09:23 ET
|
Research and Markets
Dublin, Nov. 07, 2024 (GLOBE NEWSWIRE) -- The "Chronic Obstructive Pulmonary Disease (COPD) and Asthma Devices Market Report 2024" report has been added to ResearchAndMarkets.com's offering. ...
Upstream Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights
November 07, 2024 07:00 ET
|
Upstream Bio
Upstream reports third quarter 2024 financial results and recent corporate achievements
“A meaningful first step in acknowledging decades of harm”: Lung Health Foundation Applauds Landmark $32.5 Billion Legal Settlement Against Tobacco Companies
October 18, 2024 14:10 ET
|
Lung Health Foundation
Lung Health Foundation- Canada’s premier resource on lung health research, education and advocacy- applauds Landmark Settlement Against Tobacco Companies
Global Nebulizer Market Size Projected to Reach USD 2.05 Billion by 2032, Growing at 6.57% CAGR – SNS Insider
October 18, 2024 09:00 ET
|
SNS Insider pvt ltd
Austin, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Nebulizer Market Size Analysis: "According to SNS Insider, The Nebulizer Market was valued at USD 1.16 Billion in 2023 and is projected to reach USD 2.05...
Bilevel Positive Pressure Ventilator Market to Reach $3.4 Billion, Globally, by 2033 at 5.9% CAGR: Allied Market Research
October 03, 2024 10:06 ET
|
Allied Analytics LLP
Wilmington, Delaware, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Allied Market Research published a report, titled, "Bilevel Positive Pressure Ventilator Market by Type (Fixed Pressure BiPAP Device and Auto...
Monaghan Medical Wins 2024 AARC Zenith Award
October 03, 2024 04:00 ET
|
Monaghan Medical Corporation
Monaghan Medical Corporation has been honored with the prestigious 2024 Zenith Award from the American Association for Respiratory Care (AARC). This award
Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD
September 27, 2024 09:35 ET
|
Regeneron Pharmaceuticals, Inc.
Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype Following...
Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)
September 27, 2024 07:00 ET
|
Regeneron Pharmaceuticals, Inc.
Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations, improved...
Vaping Expected to Increase COPD Health and Economic Burden by 2050
September 10, 2024 08:00 ET
|
ResMed Inc.
Vaping Expected to Increase COPD Health and Economic Burden by 2050
New ResMed-supported research presented at ERS 2024